Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model

Fuyuan Wang, Jingjing Meng, Li Zhang, Timothy Johnson, Chi Chen, Sabita Roy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Opioid analgesics are frequently prescribed in the United States and worldwide. However, serious comorbidities, such as dependence, tolerance, immunosuppression and gastrointestinal disorders limit their long-term use. In the current study, a morphine-murine model was used to investigate the role of the gut microbiome and metabolome as a potential mechanism contributing to the negative consequences associated with opioid use. Results reveal a significant shift in the gut microbiome and metabolome within one day following morphine treatment compared to that observed after placebo. Morphine-induced gut microbial dysbiosis exhibited distinct characteristic signatures, including significant increase in communities associated with pathogenic function, decrease in communities associated with stress tolerance and significant impairment in bile acids and morphine-3-glucuronide/morphine biotransformation in the gut. Moreover, expansion of Enterococcus faecalis was strongly correlated with gut dysbiosis following morphine treatment, and alterations in deoxycholic acid (DCA) and phosphatidylethanolamines (PEs) were associated with opioid-induced metabolomic changes. Collectively, these results indicate that morphine induced distinct alterations in the gut microbiome and metabolome, contributing to negative consequences associated with opioid use. Therapeutics directed at maintaining microbiome homeostasis during opioid use may reduce the comorbidities associated with opioid use for pain management.

Original languageEnglish (US)
Article number3596
JournalScientific Reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Morphine Dependence
Metabolome
Morphine
Opioid Analgesics
Dysbiosis
Comorbidity
Phosphatidylethanolamines
Deoxycholic Acid
Metabolomics
Enterococcus faecalis
Microbiota
Pain Management
Biotransformation
Bile Acids and Salts
Immunosuppression
Gastrointestinal Microbiome
Homeostasis
Therapeutics
Placebos

ASJC Scopus subject areas

  • General

Cite this

Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model. / Wang, Fuyuan; Meng, Jingjing; Zhang, Li; Johnson, Timothy; Chen, Chi; Roy, Sabita.

In: Scientific Reports, Vol. 8, No. 1, 3596, 01.12.2018.

Research output: Contribution to journalArticle

Wang, Fuyuan ; Meng, Jingjing ; Zhang, Li ; Johnson, Timothy ; Chen, Chi ; Roy, Sabita. / Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{84eb55f857654a8c8b4b7c07477130c8,
title = "Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model",
abstract = "Opioid analgesics are frequently prescribed in the United States and worldwide. However, serious comorbidities, such as dependence, tolerance, immunosuppression and gastrointestinal disorders limit their long-term use. In the current study, a morphine-murine model was used to investigate the role of the gut microbiome and metabolome as a potential mechanism contributing to the negative consequences associated with opioid use. Results reveal a significant shift in the gut microbiome and metabolome within one day following morphine treatment compared to that observed after placebo. Morphine-induced gut microbial dysbiosis exhibited distinct characteristic signatures, including significant increase in communities associated with pathogenic function, decrease in communities associated with stress tolerance and significant impairment in bile acids and morphine-3-glucuronide/morphine biotransformation in the gut. Moreover, expansion of Enterococcus faecalis was strongly correlated with gut dysbiosis following morphine treatment, and alterations in deoxycholic acid (DCA) and phosphatidylethanolamines (PEs) were associated with opioid-induced metabolomic changes. Collectively, these results indicate that morphine induced distinct alterations in the gut microbiome and metabolome, contributing to negative consequences associated with opioid use. Therapeutics directed at maintaining microbiome homeostasis during opioid use may reduce the comorbidities associated with opioid use for pain management.",
author = "Fuyuan Wang and Jingjing Meng and Li Zhang and Timothy Johnson and Chi Chen and Sabita Roy",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-21915-8",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model

AU - Wang, Fuyuan

AU - Meng, Jingjing

AU - Zhang, Li

AU - Johnson, Timothy

AU - Chen, Chi

AU - Roy, Sabita

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Opioid analgesics are frequently prescribed in the United States and worldwide. However, serious comorbidities, such as dependence, tolerance, immunosuppression and gastrointestinal disorders limit their long-term use. In the current study, a morphine-murine model was used to investigate the role of the gut microbiome and metabolome as a potential mechanism contributing to the negative consequences associated with opioid use. Results reveal a significant shift in the gut microbiome and metabolome within one day following morphine treatment compared to that observed after placebo. Morphine-induced gut microbial dysbiosis exhibited distinct characteristic signatures, including significant increase in communities associated with pathogenic function, decrease in communities associated with stress tolerance and significant impairment in bile acids and morphine-3-glucuronide/morphine biotransformation in the gut. Moreover, expansion of Enterococcus faecalis was strongly correlated with gut dysbiosis following morphine treatment, and alterations in deoxycholic acid (DCA) and phosphatidylethanolamines (PEs) were associated with opioid-induced metabolomic changes. Collectively, these results indicate that morphine induced distinct alterations in the gut microbiome and metabolome, contributing to negative consequences associated with opioid use. Therapeutics directed at maintaining microbiome homeostasis during opioid use may reduce the comorbidities associated with opioid use for pain management.

AB - Opioid analgesics are frequently prescribed in the United States and worldwide. However, serious comorbidities, such as dependence, tolerance, immunosuppression and gastrointestinal disorders limit their long-term use. In the current study, a morphine-murine model was used to investigate the role of the gut microbiome and metabolome as a potential mechanism contributing to the negative consequences associated with opioid use. Results reveal a significant shift in the gut microbiome and metabolome within one day following morphine treatment compared to that observed after placebo. Morphine-induced gut microbial dysbiosis exhibited distinct characteristic signatures, including significant increase in communities associated with pathogenic function, decrease in communities associated with stress tolerance and significant impairment in bile acids and morphine-3-glucuronide/morphine biotransformation in the gut. Moreover, expansion of Enterococcus faecalis was strongly correlated with gut dysbiosis following morphine treatment, and alterations in deoxycholic acid (DCA) and phosphatidylethanolamines (PEs) were associated with opioid-induced metabolomic changes. Collectively, these results indicate that morphine induced distinct alterations in the gut microbiome and metabolome, contributing to negative consequences associated with opioid use. Therapeutics directed at maintaining microbiome homeostasis during opioid use may reduce the comorbidities associated with opioid use for pain management.

UR - http://www.scopus.com/inward/record.url?scp=85042673081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042673081&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-21915-8

DO - 10.1038/s41598-018-21915-8

M3 - Article

C2 - 29483538

AN - SCOPUS:85042673081

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 3596

ER -